Ferronova's vision is to provide the technology to improve the surgical staging of complex cancers. Our nano-particles are visible on MRI where pre-surgical imaging is possible, are retained in the sentinel node for more flexible surgical scheduling, and overcome problems associated with other magnetic particles such as clearance from the injection site. Our research partners at the University of Sydney, the University of New South Wales, and UniSA Future Industries Institute in Adelaide Australia continue to research particles, coatings, and clinical applications to improve outcomes in cancer diagnostics and therapeutics.
The technology is targeted at Sentinel Lymph Node (SLN) Mapping. It is designed to meet the needs of surgeons treating difficult cancers such as head and neck cancer and colorectal cancer. The unique particles are designed to be retained in the sentinel node, be compatible with existing surgical equipment, and to overcome false negatives associated with shine-through, where sentinel lymph nodes close to an injection site can be missed due to inadequate resolution of alternative solutions.
*The probe and tracer are not regulatory approved or cleared in any markets.
The magnetic particles are designed to work in conjunction with Magnetometers or infrared surgical imaging equipment, eliminating the logistical and handling issues associated with alternative radioisotope tracers. The magnetic technology is well suited to complex cancers such as head and neck cancer, prostate cancer, and colorectal cancer where resolution and the ability to locate sentinel lymph nodes close to the injection site is of critical importance.